Core Laboratories Inc.
CLB
$12.62
$0.302.44%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.76% | 2.68% | 0.78% | 1.65% | 4.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.76% | 2.68% | 0.78% | 1.65% | 4.10% |
| Cost of Revenue | 5.14% | 4.42% | 1.27% | 1.20% | 1.60% |
| Gross Profit | -5.92% | -3.53% | -1.00% | 3.34% | 14.31% |
| SG&A Expenses | -0.78% | -2.82% | -2.68% | -16.49% | 3.11% |
| Depreciation & Amortization | -5.26% | -5.13% | -4.99% | -6.40% | -8.02% |
| Other Operating Expenses | -92.05% | -100.32% | -18.98% | 59.25% | 34.90% |
| Total Operating Expenses | 4.04% | 3.19% | 0.65% | -0.41% | 1.51% |
| Operating Income | -7.56% | -1.32% | 1.91% | 20.76% | 30.91% |
| Income Before Tax | 12.08% | 6.59% | -5.45% | 20.16% | 37.58% |
| Income Tax Expenses | 235.34% | 1,130.01% | 427.21% | -56.76% | -59.35% |
| Earnings from Continuing Operations | -13.16% | -34.31% | -38.72% | 59.04% | 88.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -115.14% | -1,607.41% | -187.16% | -144.89% | -70.73% |
| Net Income | -14.38% | -36.46% | -39.97% | 58.23% | 88.53% |
| EBIT | -7.56% | -1.32% | 1.91% | 20.76% | 30.91% |
| EBITDA | -7.06% | -2.16% | 0.33% | 13.85% | 19.82% |
| EPS Basic | -15.08% | -36.83% | -40.30% | 57.36% | 87.60% |
| Normalized Basic EPS | -12.12% | -8.18% | -7.16% | 22.32% | 35.30% |
| EPS Diluted | -12.65% | -36.53% | -41.44% | 54.40% | 83.79% |
| Normalized Diluted EPS | -12.22% | -8.22% | -7.33% | 21.98% | 34.85% |
| Average Basic Shares Outstanding | 0.48% | 0.76% | 0.83% | 0.90% | 0.96% |
| Average Diluted Shares Outstanding | 0.47% | 0.75% | 0.95% | 1.01% | 1.53% |
| Dividend Per Share | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Payout Ratio | 0.17% | 0.58% | 0.68% | -0.36% | -0.47% |